178 related articles for article (PubMed ID: 32598839)
1. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.
Gaikwad H; Li Y; Gifford G; Groman E; Banda NK; Saba L; Scheinman R; Wang G; Simberg D
Bioconjug Chem; 2020 Jul; 31(7):1844-1856. PubMed ID: 32598839
[TBL] [Abstract][Full Text] [Related]
2. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.
Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074
[TBL] [Abstract][Full Text] [Related]
3. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
4.
Wang G; Griffin JI; Inturi S; Brenneman B; Banda NK; Holers VM; Moghimi SM; Simberg D
Front Immunol; 2017; 8():151. PubMed ID: 28239384
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.
Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D
Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271
[TBL] [Abstract][Full Text] [Related]
6. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties.
Wang G; Inturi S; Serkova NJ; Merkulov S; McCrae K; Russek SE; Banda NK; Simberg D
ACS Nano; 2014 Dec; 8(12):12437-49. PubMed ID: 25419856
[TBL] [Abstract][Full Text] [Related]
7. Complement opsonization of nanoparticles: Differences between humans and preclinical species.
Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928
[TBL] [Abstract][Full Text] [Related]
8. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes.
van Epps DE; Chenoweth DE
J Immunol; 1984 Jun; 132(6):2862-7. PubMed ID: 6373920
[TBL] [Abstract][Full Text] [Related]
10. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
[TBL] [Abstract][Full Text] [Related]
11. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
[TBL] [Abstract][Full Text] [Related]
12. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.
Mastellos DC; Ricklin D; Hajishengallis E; Hajishengallis G; Lambris JD
Mol Oral Microbiol; 2016 Feb; 31(1):3-17. PubMed ID: 26332138
[TBL] [Abstract][Full Text] [Related]
13. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
14. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
[TBL] [Abstract][Full Text] [Related]
15. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.
Francian A; Mann K; Kullberg M
Int J Nanomedicine; 2017; 12():5149-5161. PubMed ID: 28790822
[TBL] [Abstract][Full Text] [Related]
16. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
Wang Z; Hood ED; Nong J; Ding J; Marcos-Contreras OA; Glassman PM; Rubey KM; Zaleski M; Espy CL; Gullipali D; Miwa T; Muzykantov VR; Song WC; Myerson JW; Brenner JS
Adv Mater; 2022 Feb; 34(8):e2107070. PubMed ID: 34910334
[TBL] [Abstract][Full Text] [Related]
17. Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.
Lausen M; Pedersen MS; Rahman NSK; Holm-Nielsen LT; Farah FYM; Christiansen G; Birkelund S
Infect Immun; 2020 Jun; 88(7):. PubMed ID: 32284372
[TBL] [Abstract][Full Text] [Related]
18. C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.
Tavano R; Gabrielli L; Lubian E; Fedeli C; Visentin S; Polverino De Laureto P; Arrigoni G; Geffner-Smith A; Chen F; Simberg D; Morgese G; Benetti EM; Wu L; Moghimi SM; Mancin F; Papini E
ACS Nano; 2018 Jun; 12(6):5834-5847. PubMed ID: 29750504
[TBL] [Abstract][Full Text] [Related]
19. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B; Larsson R; Hong J; Elgue G; Ekdahl KN; Sahu A; Lambris JD
Blood; 1998 Sep; 92(5):1661-7. PubMed ID: 9716594
[TBL] [Abstract][Full Text] [Related]
20. Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.
Wolf-Grosse S; Rokstad AM; Ali S; Lambris JD; Mollnes TE; Nilsen AM; Stenvik J
Int J Nanomedicine; 2017; 12():3927-3940. PubMed ID: 28579778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
